<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091260</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000385687</org_study_id>
    <secondary_id>BUMC-H-23235</secondary_id>
    <secondary_id>CELGENE-RV-AMYL-PI-003</secondary_id>
    <nct_id>NCT00091260</nct_id>
  </id_info>
  <brief_title>CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis</brief_title>
  <official_title>A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaishali Sanchorawala</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary
      systemic amyloidosis.

      PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without
      dexamethasone in treating patients with primary systemic amyloidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the tolerability of CC-5013 in patients with primary systemic (AL)
           amyloidosis.

        -  Determine the objective hematologic response rate in patients treated with this drug.

        -  Determine amyloid organ disease response in patients treated with this drug.

      Secondary

        -  Determine hematologic and amyloid organ disease response in patients who do not achieve
           a response to CC-5013 alone and are subsequently treated with CC-5013 and dexamethasone.

        -  Determine the toxicity of CC-5013 in combination with dexamethasone in these patients.

      OUTLINE: Patients receive oral CC-5013 once daily on days 1-21. Courses repeat every 28 days
      in the absence of disease progression or unacceptable toxicity. Patients not achieving a
      hematologic response continue to receive CC-5013 as before and also receive oral
      dexamethasone twice daily on days 1-4, 9-12, and 17-20 of every other 28-day course for up to
      6 courses of combination therapy. Patients who maintain a hematologic response after 6
      courses of combination therapy may receive CC-5013 alone in the absence of disease
      progression or unacceptable toxicity. Patients not achieving a hematologic response after the
      initiation of dexamethasone are removed from the study.

      Patients are followed annually.

      PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study within 5-12.5
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Removed From Study Treatment Due to Toxicities</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Hematologic Response With Single-agent CC-5013</measure>
    <time_frame>3 months</time_frame>
    <description>Complete response = Absence of detectable monoclonal protein in serum or urine by immunofixation electrophoresis, less than 5% plasma cells on bone marrow biopsy without clonal dominance of kappa or lambda isotype, and normal serum free light chain assay.
Partial response= For patients with detectable and quantifiable monoclonal marrow plasmacytosis= a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells. For patients with a detectable monoclonal peak on serum or urine protein electrophoresis= a reduction in the peak height of 50% or more.
For patients with quantifiable urinary kappa or lambda chain concentration= a 50% reduction in daily light chain excretion in 24 hour urine.
For patients with an elevated serum free light chain assay, a reduction of 50% or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Received Both CC-5013 and Dexamethasone and Had a Hematologic Response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>revlimid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.</description>
    <arm_group_label>revlimid</arm_group_label>
    <other_name>dexamethasone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone</description>
    <arm_group_label>revlimid</arm_group_label>
    <other_name>revlimid; CC-5013</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary systemic (AL) amyloidosis

               -  Tissue amyloid deposits or positive fat aspirate

          -  Meets 1 of the following criteria for AL type disease:

               -  Serum or urine monoclonal protein by immunofixation electrophoresis

               -  Plasmacytosis of bone marrow by monoclonal staining for kappa- or lambda-light
                  chain isotype

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  SWOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  White blood count&gt; 3,000/mm^3

          -  Hemoglobin &gt; 8 g/dL

          -  Platelet count &gt; 100,000/mm^3

          -  Absolute neutrophil count &gt; 1,000/mm^3

        Hepatic

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 times ULN

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Prior thalidomide for AL amyloidosis allowed

        Chemotherapy

          -  More than 4 weeks since prior cytotoxic chemotherapy

        Endocrine therapy

          -  Prior steroids for AL amyloidosis allowed

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy

        Surgery

          -  Prior surgery allowed

        Other

          -  Recovered from all prior therapy

        Exclusion Criteria:

          -  No secondary or familial amyloidosis

          -  No multiple myeloma, defined as ≥ 30% plasma cells in bone marrow biopsy specimen OR
             lytic bone lesions

          -  No prior CC-5013

        Renal

          -  No dialysis

        Cardiovascular

          -  No symptomatic cardiac arrhythmia

          -  No oxygen-dependent restrictive cardiomyopathy

        Other

          -  No untreated or uncontrolled infection

          -  No other malignancy except basal cell skin cancer or carcinoma in situ of the cervix
             or breast

          -  No other serious medical illness that would preclude study participation

          -  No history of hypersensitivity reaction to thalidomide

          -  HIV negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David C. Seldin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research Center at Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <results_first_submitted>September 9, 2016</results_first_submitted>
  <results_first_submitted_qc>December 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2017</results_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Vaishali Sanchorawala</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>primary systemic amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Revlimid</title>
          <description>lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
dexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
lenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Revlimid</title>
          <description>lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
dexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
lenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dialysis y/n</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>on dialysis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not on dialysis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Removed From Study Treatment Due to Toxicities</title>
        <time_frame>1 year</time_frame>
        <population>Number of patients who had at least one dose of CC-5013</population>
        <group_list>
          <group group_id="O1">
            <title>Revlimid</title>
            <description>lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
dexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
lenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Removed From Study Treatment Due to Toxicities</title>
          <population>Number of patients who had at least one dose of CC-5013</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Hematologic Response With Single-agent CC-5013</title>
        <description>Complete response = Absence of detectable monoclonal protein in serum or urine by immunofixation electrophoresis, less than 5% plasma cells on bone marrow biopsy without clonal dominance of kappa or lambda isotype, and normal serum free light chain assay.
Partial response= For patients with detectable and quantifiable monoclonal marrow plasmacytosis= a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells. For patients with a detectable monoclonal peak on serum or urine protein electrophoresis= a reduction in the peak height of 50% or more.
For patients with quantifiable urinary kappa or lambda chain concentration= a 50% reduction in daily light chain excretion in 24 hour urine.
For patients with an elevated serum free light chain assay, a reduction of 50% or more.</description>
        <time_frame>3 months</time_frame>
        <population>Participants who received at least 3 cycles of single-agent CC-5013 and underwent subsequent evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Revlimid</title>
            <description>lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
dexamethasone: dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
lenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hematologic Response With Single-agent CC-5013</title>
          <description>Complete response = Absence of detectable monoclonal protein in serum or urine by immunofixation electrophoresis, less than 5% plasma cells on bone marrow biopsy without clonal dominance of kappa or lambda isotype, and normal serum free light chain assay.
Partial response= For patients with detectable and quantifiable monoclonal marrow plasmacytosis= a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells. For patients with a detectable monoclonal peak on serum or urine protein electrophoresis= a reduction in the peak height of 50% or more.
For patients with quantifiable urinary kappa or lambda chain concentration= a 50% reduction in daily light chain excretion in 24 hour urine.
For patients with an elevated serum free light chain assay, a reduction of 50% or more.</description>
          <population>Participants who received at least 3 cycles of single-agent CC-5013 and underwent subsequent evaluation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Received Both CC-5013 and Dexamethasone and Had a Hematologic Response</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revlimid</title>
            <description>lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
dexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
lenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Received Both CC-5013 and Dexamethasone and Had a Hematologic Response</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Revlimid</title>
          <description>lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
dexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
lenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="ctcae v3">neutropenia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>organ rejection</sub_title>
                <description>rejection of previously transplanted heart</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>cardiac, other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Decreased Performance Status</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>gout</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever/infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <description>upper respiratory infection</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>increased INR</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>decreased phosphate</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="52" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>cardiac, other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>cushingoid</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>visual disturbance</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>early satiety</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Change in appetite</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>hemorrhoids</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>GI other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>hemorrhage - nose</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="61" subjects_affected="54" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Decreased performance status</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Weight change</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>dry membranes</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="45" subjects_affected="42" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>tremors</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>flu-like syndrome</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>post nasal drip</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever/infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>pulmonary infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="43" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>increased alkylase phosphate</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>increased alanine aminotransferase test</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>elevated blood urea nitrogen blood test</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle cramps</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>pain - muscle</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>spasms</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>numbness - extremities</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>pain - extremities</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>tingling - extremities</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mood alteration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>dysuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>itching</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Derm/skin other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Easy bruising</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vaishali Sanchorawala</name_or_title>
      <organization>Boston Medical Center</organization>
      <phone>6176386521</phone>
      <email>vaishali.sanchorawala@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

